NRx Pharma Tackles Suicidal Depression
Investors and biotech watchers — NRx Pharmaceuticals is leading a potential breakthrough in the treatment of suicidal depression and PTSD. In this New to The Street interview, co-CEO Jonathan Javitt discusses the company’s application for the FDA’s Commissioner’s National Priority Voucher — aimed at accelerating approval for life-saving therapies.
NRx is targeting suicidal ideation with unprecedented speed and neuroplastic impact. With over 180,000 real-world data points and plans for FDA approval by year-end, the company is also advancing a next-generation follow-up drug (NRX-101) and transcranial magnetic stimulation to support long-term treatment.
Learn how NRx is addressing one of America’s most urgent mental health crises through innovation, safety, and fast-track regulatory strategy.
🏷️ Tags:
#NRxPharma #SuicidalDepression #MentalHealthInnovation #FDAApproval #BiotechNews #PTSDTreatment #NRX101 #Neuroplasticity #PreservativeFreeDrugs #PriorityVoucher #HopeTherapeutics #NewToTheStreet #JonathanJavitt #MentalHealthCrisis #PharmaInvestors
